Given that patients with one or more tumor regions exhibiting IDH signature may all potentially benefit from IDH targeted therapies, a patient should be classified as IDH‐SG as long as one tumor region from this patient was classified as IDH‐SG. The gene discussed is IDH1; the disease is neoplasm.